Reports of Biochemistry
and Molecular Biology
Sat, Dec 21, 2024
[Archive]
Volume 12, Issue 2 (Vol.12 No.2 Jul 2023)
rbmb.net 2023, 12(2): 332-339 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mamdouh Shoeib S, Elwy Abdeldaim D, Samir Mashal S, Raafat Ibrahim R, Mohamed Dawood L, Shatat D, et al . The Ratio of Cysteine-Rich Angiogenic Inducer 61 to MicroRNA -155 Expression as a Preeclampsia Diagnostic Marker and Predictor of Its Severity. rbmb.net 2023; 12 (2) :332-339
URL: http://rbmb.net/article-1-1185-en.html
URL: http://rbmb.net/article-1-1185-en.html
Sarah Mamdouh Shoeib 
, Doaa Elwy Abdeldaim , Shimaa Samir Mashal , Rowida Raafat Ibrahim * , Lamees Mohamed Dawood , Doaa Shatat , Yasmine Ibrahim El-Masry , Ahmed Almeldin , Radwa Mahamoud El Sharaby
, Doaa Elwy Abdeldaim , Shimaa Samir Mashal , Rowida Raafat Ibrahim * , Lamees Mohamed Dawood , Doaa Shatat , Yasmine Ibrahim El-Masry , Ahmed Almeldin , Radwa Mahamoud El Sharaby
Medical Biochemistry & Molecular Biology Department, Faculty of Medicine, Tanta University, Egypt.
Abstract: (1057 Views)
Background: Preeclampsia (PE) is a multisystem pregnancy disorder that increases maternal-perinatal morbidity and mortality significantly. MicroRNA-155 (miR-155) overexpression in the sera of pregnant women has been linked to preeclampsia. Researchers discovered that miR-155 acts during pregnancy by down-regulating and reducing the cysteine-rich angiogenic inducer 61 (CYR61), which causes local ischemia as well as oxidative stress.
Methods: The level of miR-155 expression in all serum samples was quantified using real-time polymerase chain reaction (RT-PCR), and serum CYR61 was measured using enzyme-linked immunosorbent assays. Together with the Cyr-61/miR-155 ratio, they were evaluated as biomarkers for PE pathogenesis and severity prediction.
Results: MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 ratios were all significantly higher in PE patients compared to the control group. Serum CYR61 levels and the Cyr-61/miR-155 ratio differed significantly between mild and severe PE patients.
Conclusion: MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 may serve as biomarkers for PE pathogenesis and severity prediction.
Methods: The level of miR-155 expression in all serum samples was quantified using real-time polymerase chain reaction (RT-PCR), and serum CYR61 was measured using enzyme-linked immunosorbent assays. Together with the Cyr-61/miR-155 ratio, they were evaluated as biomarkers for PE pathogenesis and severity prediction.
Results: MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 ratios were all significantly higher in PE patients compared to the control group. Serum CYR61 levels and the Cyr-61/miR-155 ratio differed significantly between mild and severe PE patients.
Conclusion: MiR-155 expression, serum CYR61 levels, and Cyr-61/miR-155 may serve as biomarkers for PE pathogenesis and severity prediction.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2023/05/29 | Accepted: 2023/08/18 | Published: 2023/12/20
Received: 2023/05/29 | Accepted: 2023/08/18 | Published: 2023/12/20
References
1. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275-289. [DOI:10.1038/s41581-019-0119-6] [PMID] []
2. Gathiram P, Moodley J. Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovasc J Afr. 2016;27(2):71-8. [DOI:10.5830/CVJA-2016-009] [PMID] []
3. Koushki M, Amiri Dash Atan N, Omidi-Ardali H, Rezaei Tavirani M. Assessment of Correlation Between miR-210 Expression and Pre-Eclampsia Risk: A Meta-Analysis. Rep Biochem Mol Biol. 2018;7(1):94-101.
4. Zhang Y, Diao Z, Su L, Sun H, Li R, Cui H, Hu Y. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol. 2010;202(5):466. [DOI:10.1016/j.ajog.2010.01.057] [PMID]
5. Al-Kawaz HS, Yasser OM, Mousa MJ. A New Method to Estimate Inhibition Percentage of Endogenous Digitalis in Patients with Pre-eclampsia. Rep Biochem Mol Biol. 2022;11(1):138-145. [DOI:10.52547/rbmb.11.1.138] [PMID] []
6. Luo R, Wang Y, Xu P, Cao G, Zhao Y, Shao X, Li YX, Chang C, Peng C, Wang YL. Hypoxia-inducible miR-210 contributes to preeclampsia via targeting thrombospondin type I domain containing 7A. Sci Rep. 2016;6:19588. [DOI:10.1038/srep19588] [PMID] []
7. Addo KA, Palakodety N, Hartwell HJ, Tingare A, Fry RC. Placental microRNAs: Responders to environmental chemicals and mediators of pathophysiology of the human placenta. Toxicol Rep. 2020;7:1046-1056. [DOI:10.1016/j.toxrep.2020.08.002] [PMID] []
8. Xu P, Ma Y, Wu H, Wang YL. Placenta-Derived MicroRNAs in the Pathophysiology of Human Pregnancy. Front Cell Dev Biol. 2021;9:646326. [DOI:10.3389/fcell.2021.646326] [PMID] []
9. Vashukova ES, Glotov AS, Baranov VS. MicroRNAs Associated with Preeclampsia. Russ J Genet. 2020; 56(1):1-16. [DOI:10.1134/S1022795419080167]
10. Zhang M, Muralimanoharan S, Wortman AC, Mendelson CR. Primate-specific miR-515 family members inhibit key genes in human trophoblast differentiation and are upregulated in preeclampsia. Proc Natl Acad Sci U S A. 2016;113(45):E7069-E7076. [DOI:10.1073/pnas.1607849113] [PMID] []
11. Kolkova Z, Holubekova V, Grendar M, Nachajova M, Zubor P, Pribulova T, Loderer D, et al. Association of Circulating miRNA Expression with Preeclampsia, Its Onset, and Severity. Diagnostics (Basel). 2021;11(3):476. [DOI:10.3390/diagnostics11030476] [PMID] []
12. Han L, Liu X, Li H, Zou J, Yang Z, Han J, et al. Blood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS One. 2014;9(12):e114488. [DOI:10.1371/journal.pone.0114488] [PMID] []
13. Namvar Jahromi B, Rafiee SH. Coagulation factors in severe preeclampsia. Iran Red Crescent Med J. 2009; 11(3): 321-324.
14. Feldstein O, Kovo M, Tal O, Braunstein M, Grinstein E, Schreiber L, Bar J, Weiner E. The association between abnormal coagulation testing in preeclampsia, adverse pregnancy outcomes, and placental histopathology. Hypertens Pregnancy. 2019;38(3):176-183. [DOI:10.1080/10641955.2019.1638396] [PMID]
15. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(9):542-52. [DOI:10.1038/nrgastro.2013.87] [PMID] []
16. Dong X, Gou W, Li C, Wu M, Han Z, Li X, Chen Q. Proteinuria in preeclampsia: Not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertens. 2017;8:60-64. [DOI:10.1016/j.preghy.2017.03.005] [PMID]
17. Chung WH, To WWK. Outcome of pregnancy with new onset proteinuria and progression to pre-eclampsia: A retrospective analysis. Pregnancy Hypertens. 2018;12:174-177. [DOI:10.1016/j.preghy.2017.11.007] [PMID]
18. Gan L, Liu Z, Wei M, Chen Y, Yang X, Chen L, Xiao X. MiR-210 and miR-155 as potential diagnostic markers for pre-eclampsia pregnancies. Medicine (Baltimore). 2017;96(28):e7515. [DOI:10.1097/MD.0000000000007515] [PMID] []
19. Jairajpuri DS, Malalla ZH, Mahmood N, Almawi WY. Circulating microRNA expression as predictor of preeclampsia and its severity. Gene. 2017;627:543-548. [DOI:10.1016/j.gene.2017.07.010] [PMID]
20. Youssef HMG, Marei ES. Association of MicroRNA-210 and MicroRNA-155 with severity of preeclampsia. Pregnancy Hypertens. 2019;17:49-53. [DOI:10.1016/j.preghy.2019.05.010] [PMID]
21. Gellhaus A, Schmidt M, Dunk C, Lye SJ, Kimmig R, Winterhager E. Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. Mol Hum Reprod. 2006;12(6):389-99. [DOI:10.1093/molehr/gal044] [PMID]
22. Wang Z, Shan Y, Yang Y, Wang T, Guo Z. MicroRNA-155 is upregulated in the placentas of patients with preeclampsia and affects trophoblast apoptosis by targeting SHH/GLi1/BCL2. Hum Exp Toxicol. 2021;40(3):439-451. [DOI:10.1177/0960327120954252] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
